Company (Location) |
Company (Location) |
Value (M) |
Type/Product Area |
Terms/Details (Date) |
JUNE | ||||
D-Pharm Ltd. (Rehovot, Israel) |
Jiangsu NHWA Pharmaceutical Co. Ltd. (China) |
ND |
Partnership to commercialize D-Pharm's DP-VPA therapy for Epilepsy in China |
D-Pharm will receive up-front and developmental milestone payments, plus sales bonuses and royalties (6/1) |
Ligand Pharmaceuticals Inc. (San Diego) |
Merck & Co. Inc. (Whitehouse Station, N.J.) |
ND |
Captisol supply agreement for an undisclosed program |
Ligand will supply clinical and commercial supplies of Captisol and, if the program is approved for commercialization, expects to deliver multiple metric tons annually (6/21) |
Medivir AB (Huddinge, Sweden) |
Daewoong Pharmaceutical Co. Ltd. (Seoul, South Korea) |
ND |
Agreement to distribute Xerclear, a cold sore treatment, in China and Hong Kong |
Daewoong will carry out clinical studies and obtain regulatory approval for marketing and sales of the product in those territories; Medivir will be eligible for royalties (6/24) |
JULY | ||||
Merck & Co. Inc. (Whitehouse Station, N.J.) |
Roche AG (Basel, Switzerland) |
ND |
Nonexclusive deal for the global promotion of protease inhibitor Victrelis as part of a triple combination therapy regimen with peginterferon alfa and ribavirin |
The firms previously disclosed an agreement to promote Victrelis in the U.S., where it gained marketing approval this year (7/21) |
Victory Pharma Inc. (San Diego) |
Shionogi Inc. (Florham Park, N.J.) |
$127 |
Agreement for Shionogi to acquire all currently marketed products from Victory, including seven treatments for pain and two for infectious diseases |
The FDA-approved products will be marketed by Shionogi's existing sales force; terms indicated a $118M cash payment at closing with up to $9M in additional milestone payments (7/19) |
Wellstat Therapeutics Corp. (Gaithersburg, Md.) |
BTG International Inc. (London) |
ND |
Deal for U.S. marketing rights for uridine triacetate to treat accidental overexposure to chemotherapy drug fluorouracil due to dosing errors or imparied clearance from the body |
BTG gains rights in the U.S. for up to 10 years after approval, while Wellstat retains them outside the U.S. and for all other potential uses; Wellstat gets an up-front payment, milestone payments, transfer pricing payments based on manufacturing costs and a significant percentage of net sales (7/7) |
Notes: The date indicated refers to the BioWorld Today issue in which the news item can be found. ** Denotes the date the item ran in BioWorld International. This chart may include collaborations between two pharmaceutical companies that involve a biotech product. |